伊布替尼作为套细胞淋巴瘤一线治疗:一项英国多中心真实世界研究
新冠疫情期间,英格兰批准伊布替尼单用或联合利妥昔单抗替代免疫化疗用于初治套细胞淋巴瘤(MCL)。该多中心观察性队列纳入149例未治MCL成人,评估毒性、疗效与生存。中位随访15.6个月,总缓解率71.2%、完全缓解率20.2%,中位无进展生存26.0个月;高危患者无进展生存和总生存均显著更差。
要点
- 149例初治MCL中36.2%为高危,中位年龄75岁,8.9%为自体移植候选者。
- 中位随访15.6个月,总缓解率71.2%、完全缓解率20.2%,中位无进展生存26.0个月。
- 高危患者无进展生存13.7个月 vs 低危未达到(HR 2.19,P=.004),总生存14.8个月 vs 未达到(HR 2.36,P=.005)。
核心结论
- 伊布替尼单用或联合利妥昔单抗作为MCL一线治疗有效且耐受性良好,包括老年和移植不适合患者。
- 约三分之一高危患者以及不适合伊布替尼后治疗者,无进展生存和总生存显著较差,提示这些人群需要新方法。
研究设计与样本
- 观察性队列研究,评估伊布替尼单用或联合利妥昔单抗治疗未治MCL成人的安全性、疗效和生存。
- 来自43个参与中心共149例患者:男性74.1%,中位年龄75岁,ECOG 0-1占75.2%,高危占36.2%,自体移植候选者占8.9%。
- 所有患者接受至少1周期伊布替尼(中位8周期),39.0%联合利妥昔单抗。
主要发现
- 3级及以上毒性发生率20.3%,33.8%需要减量或延迟给药。
- 中位随访15.6个月,41.6%停用伊布替尼,其中8.1%因毒性停药。
- 104例可评估缓解者中,总缓解率71.2%,完全缓解率20.2%。
- 总缓解率:低危77.3% vs 高危59.0%(P=.05);伊布替尼-利妥昔单抗组78.7% vs 伊布替尼单药组64.9%(P=.13)。
- 中位无进展生存:全体26.0个月;高危13.7个月 vs 低危未达到(HR 2.19,P=.004)。
关键数值与推荐
- 高危MCL定义:TP53突变/缺失/p53过表达、母细胞样/多形性,或Ki67≥30%。
- 3级及以上毒性发生率20.3%,减量/延迟给药率33.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high-risk, and 8.9% autologous transplant candidates. All patients received ≥1 cycle ibrutinib (median, 8 cycles), 39.0% with rituximab. Grade ≥3 toxicity occurred in 20.3%, and 33.8% required dose reductions/delays. At 15.6-month median follow-up, 41.6% discontinued ibrutinib, 8.1% due to toxicity. Of 104 response-assessed patients, overall (ORR) and complete response (CR) rates were 71.2% and 20.2%, respectively. ORR was 77.3% (low risk) vs 59.0% (high risk) (P = .05) and 78.7% (ibrutinib-rituximab) vs 64.9% (ibrutinib; P = .13). Median progression-free survival (PFS) was 26.0 months (all patients); 13.7 months (high risk) vs not reached (NR) (low risk; hazard ratio [HR], 2.19; P = .004). Median overall survival was NR (all); 14.8 months (high risk) vs NR (low risk; HR, 2.36; P = .005). Median post-ibrutinib survival was 1.4 months, longer in 41.9% patients receiving subsequent treatment (median, 8.6 vs 0.6 months; HR, 0.36; P = .002). Ibrutinib with or without rituximab was effective and well tolerated as first-line treatment of MCL, including older and transplant-ineligible patients. PFS and OS were significantly inferior in one-third of patients with high-risk disease and those unsuitable for post-ibrutinib treatment, highlighting the need for novel approaches in these groups.
引用
- Tivey A, Shotton R, Eyre TA, et al. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study. Blood Adv. 2024. PMID: 38127279. doi:10.1182/bloodadvances.2023011152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。